Holen Sie sich die Stockscreener-App
5.23
0.95%
-0.05
Handel nachbörslich:
5.39
0.16
+3.06%
Minerva Neurosciences Inc Aktie (NERV) Neueste Nachrichten
Minerva Neurosciences sets June 2026 date for annual stockholder meeting - investing.com
Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline - TipRanks
Minerva Neurosciences sets June 3, 2026 annual meeting; stockholder notice deadlines announced - TradingView
Minerva Neurosciences (NASDAQ: NERV) sets 2026 meeting and proposal deadlines - stocktitan.net
Minerva Neurosciences Appoints New Chief Business Officer, Counsel - The Globe and Mail
Minerva Neurosciences names Jim O’Connor as chief business officer By Investing.com - Investing.com Canada
Minerva Announces Leadership Transition - Bitget
Minerva announces leadership transition - MarketScreener
Minerva Neurosciences Appoints Dr. Sheila O’Connor as President and CEO Following Leadership Transition - geneonline.com
Minerva Neurosciences names Jim O’Connor as chief business officer - investing.com
Leadership shift at Minerva Neurosciences (NASDAQ: NERV) as O’Connor joins - stocktitan.net
[Form 4] Minerva Neurosciences, Inc. Insider Trading Activity - stocktitan.net
NERV Technical Analysis & Stock Price Forecast - Intellectia AI
Minerva (NERV): Initiates Key Phase 3 Trial for Schizophrenia Tr - GuruFocus
Minerva (NERV): Initiates Key Phase 3 Trial for Schizophrenia Treatment - GuruFocus
Federated Hermes sells 3,658 shares of NERV common stock (NASDAQ: NERV) - stocktitan.net
Federated Hermes sells 97,549 NERV shares (NASDAQ: NERV) in Form 144 notice - stocktitan.net
NERV (NASDAQ: NERV) Form 144 shows 156,410-share sale, 650,000 offered - stocktitan.net
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia - The Manila Times
No approved drug exists for these schizophrenia symptoms; Minerva starts Phase 3 - stocktitan.net
Profit Recap: What is the earnings history of Minerva Neurosciences Inc2026 Bull vs Bear & Detailed Earnings Play Strategies - baoquankhu1.vn
Minerva Neurosciences: Plodding Ahead After Another Roluperidone Delay In Negative Symptoms Of Schizophrenia - Seeking Alpha
Guidance Update: Can Minerva Neurosciences Inc stock outperform in a bear market2026 Recap & Technical Pattern Recognition Alerts - baoquankhu1.vn
Short Interest in Minerva Neurosciences, Inc (NASDAQ:NERV) Grows By 27.8% - marketbeat.com
Minerva Neurosciences Stock Hits Near 2-Year High On FDA Pathway, $200M Boost — Retail Sees FDA Catalyst - MSN
Minerva Neurosciences : Olanzapine added to Roluperidone, in patients with negative symptoms (NS) of schizophrenia - marketscreener.com
Minerva Neurosciences (NERV) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $NERV - marketbeat.com
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026 - investingnews.com
Minerva Neurosciences Presents Data from its Open-label - GlobeNewswire
Schizophrenia drug combo showed no safety issues as Phase 3 starts - stocktitan.net
Market Overview: Can Minerva Neurosciences Inc continue delivering strong returns2026 Catalysts & High Conviction Buy Zone Picks - baoquankhu1.vn
Minerva Neurosciences Touts Roluperidone Data, FDA-Aligned Trial Plan for Schizophrenia Symptoms - marketbeat.com
[EFFECT] Minerva Neurosciences, Inc. SEC Filing - Stock Titan
Minerva Neurosciences, IncCommon Stock (NQ: NERV - markets.chroniclejournal.com
HC Wainwright Has Bullish Forecast for NERV Q1 Earnings - MarketBeat
Minerva Neurosciences shareholders approve key governance measures - MSN
What is HC Wainwright's Forecast for NERV Q1 Earnings? - MarketBeat
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum - Investing News Network
NERV: HC Wainwright & Co. Raises Price Target to $7.00, Maintains Neutral Rating | NERV Stock News - GuruFocus
H.C. Wainwright raises Minerva Neurosciences price target on trial design By Investing.com - Investing.com Canada
Minerva Neurosciences: Q4 Earnings Snapshot - theheraldreview.com
CNS therapies firm Minerva joins Stifel 2026 virtual forum webcast - stocktitan.net
Minerva Neurosciences (NERV) Advances Toward Phase 3 Trial with FDA Support - GuruFocus
Minerva Neurosciences Announces $80M Financing and Plans Phase 3 Trial for Roluperidone in Schizophrenia with Results Expected 2H 2027 - Minichart
Minerva Neurosciences (NASDAQ:NERV) Issues Quarterly Earnings Results - MarketBeat
Minerva Neurosciences (NERV) registers $200M shelf for stock, debt and warrants - Stock Titan
Minerva Neurosciences, Inc (NERV) Reports Q4 Earnings - AlphaStreet
Minerva Neurosciences: Fourth Quarter Financial Overview - Bitget
Minerva Neurosciences Q4 & 2025 Financials: Annual Loss of $293.4MNews and Statistics - IndexBox
Minerva Neurosciences 10-K: Revenue $0, EPS (34.67) on large net loss - TradingView
Minerva Neurosciences Q4 net loss widens on non-cash financing charges - TradingView
Minerva Neurosciences Reports $283.7M Q4 Net Loss; $82.4M Cash at Year-End - TradingView
Minerva Neurosciences Reports Q4 and Full-Year 2025 Financial Results and Updates on Roluperidone Development for Schizophrenia Treatment - Quiver Quantitative
BRIEF-Minerva Neurosciences Q4 Net Income USD -283.668 Million - TradingView
Minerva readies 2026 trial for drug aimed at schizophrenia’s ‘negative’ symptoms - Stock Titan
Minerva Neurosciences (NASDAQ: NERV) books big 2025 loss after warrant-heavy raise - stocktitan.net
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):